Lifecare ASA — Share Issue/Capital Change 2026

Jan 21, 2026

Lifecare ASA: Preliminary results of the Rights Issue

Lifecare ASA: Preliminary results of the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE

PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the previous stock exchange announcements by Lifecare ASA

("Lifecare" or the "Company") regarding the partially underwritten rights

issue of new shares in the Company (the "Offer Shares") with preferential

subscription rights for existing shareholders, raising gross proceeds of

minimum NOK 80 million and up to NOK 100 million (the "Rights Issue").

Subscribers in the Rights Issue will, without cost, receive warrants in two

series: (a) three (3) warrants for every four (4) Offer Shares allocated to,

and paid by, them in the Rights Issue, which will be exercisable in the

exercise period from 2 March 2026 to 13 March 2026 ("Warrants Series 1"); and

(b) three (3) warrants for every four (4) Offer Shares allocated to, and paid

by, them in the Rights Issue, which will be exercisable in the exercise period

from 1 June 2026 to 12 June 2026 ("Warrants Series 2" and together with

Warrants Series 1, the "Warrants").

The subscription period for the Rights Issue expired at 16:30 (CET) today, 21

January 2026.

Preliminary counting indicates that the Company has received subscriptions for

approximately 142.8 million Offer Shares. This corresponds to the subscription

of approximately 214 million Warrants in the Rights Issue. Based on this, the

Company expects to issue 160 million Offer Shares in the Rights Issue at the

subscription price of NOK 0.50 per Offer Share, and as such raise gross

proceeds of NOK 80 million.

The final allocation of the Offer Shares and the Warrants will take place on

or about 22 January 2026 in accordance with the allocation criteria set out in

the prospectus for the Rights Issue dated 6 January 2026 (the "Prospectus").

The final result of the Rights Issue will be published shortly thereafter, and

notifications regarding the allocation of the Offer Shares and Warrants, and

the corresponding subscription amount to be paid by each subscriber, are

expected to be distributed on or about 22 January 2026.

The due date for payment for the Offer Shares is 26 January 2026 (subscribers

must ensure that sufficient funds are available in their accounts on 23

January 2026).

DNB Carnegie, a part of DNB Bank ASA, and SB1 Markets AS are acting as

managers in the Rights Issue (the "Managers").

Important information

This announcement does not constitute an offer of securities for sale or a

solicitation of an offer to purchase securities of the Company in the United

States or any other jurisdiction. Copies of this announcement may not be sent

to jurisdictions, or distributed in or sent from jurisdictions, in which this

is barred or prohibited by law. The securities of the Company may not be

offered or sold in the United States absent registration or an exemption from

registration under the U.S. Securities Act of 1933, as amended (the "U.S.

Securities Act"). The securities of the Company have not been, and will not

be, registered under the U.S. Securities Act. Any sale in the United States of

the securities mentioned in this communication will be made solely to

"qualified institutional buyers" as defined in Rule 144A under the U.S.

Securities Act. No public offering of the securities will be made in the

United States.

Any offering of the securities referred to in this announcement will be made

by means of the Prospectus. This announcement is an advertisement and is not a

prospectus for the purposes of Regulation (EU) 2017/1129 of the European

Parliament and of the Council of 14 June 2017 on prospectuses to be published

when securities are offered to the public or admitted to trading on a

regulated market, and repealing Directive 2003/71/EC (as amended) as

implemented in any EEA Member State (the "Prospectus Regulation"). Investors

should not subscribe for any securities referred to in this announcement

except on the basis of information contained in the Prospectus. Copies of the

Prospectus will, following publication, be available from the Company's

registered office and, subject to certain exceptions, on the websites of the

Managers..

This announcement is not for publication or distribution in, directly or

indirectly, Australia, Canada, Japan, the United States, or any other

jurisdiction in which such release, publication or distribution would be

unlawful, and it does not constitute an offer or invitation to subscribe for

or purchase any securities in such countries or in any other jurisdiction. In

particular, the document and the information contained herein should not be

distributed or otherwise transmitted into the United States or to publications

with a general circulation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issue

and no one else and will not be responsible to anyone other than the Company

for providing the protections afforded to their respective clients or for

providing advice in relation to the Rights Issue or any transaction or

arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking

statements. Forward-looking statements are statements that are not historical

facts and may be identified by words such as "anticipate", "believe",

"continue", "estimate", "expect", "intends", "may", "should", "will" and

similar expressions. The forward-looking statements in this release are based

upon various assumptions, many of which are based, in turn, upon further

assumptions. Although the Company believes that these assumptions were

reasonable when made, these assumptions are inherently subject to significant

known and unknown risks, uncertainties, contingencies, and other important

factors which are difficult or impossible to predict and are beyond its

control. Such risks, uncertainties, contingencies, and other important factors

could cause actual events to differ materially from the expectations expressed

or implied in this release by such forward-looking statements. The

information, opinions and forward-looking statements contained in this

announcement speak only as at its date and are subject to change without

notice. This announcement is made by and is the responsibility of the Company.

Neither the Managers nor any of their respective affiliates make any

representation as to the accuracy or completeness of this announcement and

none of them accepts any responsibility for the contents of this announcement

or any matters referred to herein.

This announcement is for information purposes only and is not to be relied

upon in substitution for the exercise of independent judgment. It is not

intended as investment advice and under no circumstances is it to be used or

considered as an offer to sell, or a solicitation of an offer to buy any

securities or a recommendation to buy or sell any securities of the Company.

No reliance may be placed for any purpose on the information contained in this

announcement or its accuracy, fairness, or completeness. Neither the Managers

nor any of their respective affiliates accept any liability arising from the

use of this announcement.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 17. The information was submitted for publication,

through the agency of the contact persons set out above, at 2026-01-21 20:16

CET.